Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

Conditions

• Lung Neoplasms
• Carcinoma, Non-Small-Cell Lung
• Lung Diseases
• Adenocarcinoma

Interventions

• DRUG: CK-101

Sponsor

Checkpoint Therapeutics, Inc.